Stockscreener 앱 받기
13.71
1.08%
-0.241
Avalo Therapeutics Inc 주식(AVTX)의 최신 뉴스
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - Investing.com
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX Stock News - GuruFocus
BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Avalo Therapeutics stock maintains Buy rating at BTIG ahead of trial - Investing.com
Key facts: Avalo Therapeutics posts $78.3M 2025 loss; Q4 EPS -$1.13 - TradingView
Guggenheim reiterates Buy rating on Avalo Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim reiterates Buy rating on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics Reports 2025 Financial Results and Prepares for Key Phase 2 LOTUS Trial Data of AVTX-009 in Hidradenitis Suppurativa - Minichart
Avalo Therapeutics 2025 Annual Report: Clinical Pipeline, Regulatory Risks, and Competitive Landscape - Minichart
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avalo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avalo Therapeutics (NASDAQ:AVTX) Releases Quarterly Earnings Results, Beats Expectations By $1.17 EPS - MarketBeat
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates - The Manila Times
AVTX: 2025 saw higher R&D spending and net loss, with cash runway projected into 2028 - TradingView
Avalo 10-K: $0.0M Revenue, $78.3M Net Loss — Outlook Through 2028 - TradingView
Avalo Therapeutics (NASDAQ: AVTX) outlines HS trial plans and cash runway - Stock Titan
Avalo Therapeutics (Nasdaq: AVTX) details 2025 loss and LOTUS trial plans - Stock Titan
Avalo nears Q2 results in 250-patient skin disease drug trial - Stock Titan
Earnings Scheduled For March 23, 2026 - Sahm
If You Invested $1,000 in Avalo Therapeutics Inc (AVTX) - Stock Titan
Aug Sectors: Is Avalo Therapeutics Inc a potential multi baggerEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AVTX Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Cantor Fitzgerald L. P. Makes New $1.08 Million Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Top Executive Makes Major Move With Avalo Therapeutics Stock - TipRanks
Avalo Therapeutics chief medical officer sells $411k in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $411,695.80 in Stock - MarketBeat
Avalo Therapeutics chief medical officer sells $411k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO exercises options, sells 25,492 common shares - Stock Titan
Panic Selling: Is Avalo Therapeutics Inc undervalued by DCF analysisOptions Play & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - MarketBeat
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World
FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan
Avalo Therapeutics (AVTX) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Avalo Therapeutics (AVTX) CSO awarded 95,000 stock options - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CBO awarded 95,000 stock options - Stock Titan
Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation - Stock Titan
Avalo Therapeutics (AVTX) CEO awarded 286,000-share stock option grant - Stock Titan
Millennium Management LLC Acquires Additional Shares in Avalo Th - GuruFocus
RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTX Should I Buy - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference - Yahoo Finance
AVTX: AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter - TradingView
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com South Africa
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - MSN
0.99%
3.03%
자본화:
|
볼륨(24시간):